Artiva Biotherapeutics, Inc.
ARTVFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Artiva Biotherapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Artiva Biotherapeutics, Inc. — 10-K filed Mar 24, 2025
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 3 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 29, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Artiva Biotherapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-05-19 · Aslan Fred: Larger than all 8 other insider sales of Common Stock on file. SEC filing
- 2026-05-11 · RA Capital Healthcare Fund LP: Larger than 17 of the 18 other insider purchases of Common Stock on file. SEC filing
- 2024-07-22 · RA Capital Healthcare Fund LP: Larger than all 18 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2026-05-11–2026-05-11: 3 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2024-07-22–2024-07-22: 8 event(s) across 5 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-26 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +1,876 | 8.98 | SEC filing |
| 2026-06-25 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +31,000 | 8.88 | SEC filing |
| 2026-06-16 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +124,893 | 8.89 | SEC filing |
| 2026-06-15 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +15,414 | 8.99 | SEC filing |
| 2026-06-12 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +391,019 | 8.57 | SEC filing |
| 2026-06-11 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +548,580 | 7.91 | SEC filing |
| 2026-06-10 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +103 | 7.00 | SEC filing |
| 2026-06-09 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +479,039 | 6.91 | SEC filing |
Showing 8 of 19 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-18 | Miralles Gines Diego · President & Head of R&D | Common Stock | A — Grant, award, or other acquisition | +77,500 | SEC filing |
| 2026-05-18 | Miralles Gines Diego · President & Head of R&D | Employee Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +232,500 | SEC filing |
| 2026-03-10 | Huston Thad Allen · Chief Financial Officer | Common Stock | A — Grant, award, or other acquisition | +220,000 | SEC filing |
| 2026-02-18 | Sorg Elaine K. · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +27,500 | SEC filing |
| 2026-02-15 | Raymon Heather · SVP, Research and Development | Common Stock | A — Grant, award, or other acquisition | +46,000 | SEC filing |
| 2026-02-15 | Banerjee Subhashis · Chief Medical Officer | Common Stock | A — Grant, award, or other acquisition | +102,000 | SEC filing |
| 2026-02-15 | Horan Christopher · Chief Tech Operations Officer | Common Stock | A — Grant, award, or other acquisition | +117,300 | SEC filing |
| 2026-02-15 | Bush Jennifer · COO, CLO, Secy, Compliance Off | Common Stock | A — Grant, award, or other acquisition | +117,300 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-12-12 | Aslan Fred · President and CEO | Employee Stock Option (Right to Buy) | D — Disposition to the issuer | −257,319 | SEC filing |
| 2025-12-12 | Aslan Fred · President and CEO | Employee Stock Option (Right to Buy) | D — Disposition to the issuer | −113,999 | SEC filing |
| 2025-12-12 | Raymon Heather · SVP, Research and Development | Employee Stock Option (Right to Buy) | D — Disposition to the issuer | −18,239 | SEC filing |
| 2025-12-12 | Raymon Heather · SVP, Research and Development | Employee Stock Option (Right to Buy) | D — Disposition to the issuer | −11,399 | SEC filing |
| 2025-12-12 | Horan Christopher · Chief Tech Operations Officer | Employee Stock Option (Right to Buy) | D — Disposition to the issuer | −20,519 | SEC filing |
| 2025-12-12 | Horan Christopher · Chief Tech Operations Officer | Employee Stock Option (Right to Buy) | D — Disposition to the issuer | −77,519 | SEC filing |
| 2025-12-12 | Raymon Heather · SVP, Research and Development | Employee Stock Option (Right to Buy) | D — Disposition to the issuer | −12,539 | SEC filing |
| 2025-12-12 | Bush Jennifer · COO, CLO, Secy, Compliance Off | Employee Stock Option (Right to Buy) | D — Disposition to the issuer | −20,519 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.